Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Promitil plus external beam radiotherapy in adults with unresectable advanced cancer
MOH_2018-11-28_002503Phase 2Completed
- Sponsor
- דר' אלי ספיר
- Start
- Jun 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Mitomycin-c lipidic prodrug in cancer, sponsored by דר' אלי ספיר. Primary endpoints: Safety of Promitil in combination with external beam radiotherapy and Response rate of Promitil in combination with external beam radiotherapy. Started Jun 2018; status: completed.
02
Drugs
Mitomycin-c lipidic prodrug
03
Conditions
cancer
Beyond the preview
Go deeper on MOH_2018-11-28_002503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-28_002503.